To date, there is only one study reporting increased IL-29 (IFN-λ1) and IL-28A (IFN-λ2) serum levels in acute brucellosis patients as compared with patients after standard anti-brucellosis treatment [275], without any assumption regarding the putative role of these type III IFNs during the acute or chronic phase of brucellosis. The gene discussed is IFNL2; the disease is brucellosis.